CHARLES RIVER LABORATORIES (CRL) Stock Price, Forecast & Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
CRL Key Statistics, Chart & Performance
The current stock price of CRL is 180.07 USD. In the past month the price increased by 1.55%. In the past year, price decreased by -0.49%.
CRL Latest News, Press Relases and Analysis
CRL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.33 | 214.25B | ||
| DHR | DANAHER CORP | 27.94 | 154.22B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.09 | 47.98B | ||
| A | AGILENT TECHNOLOGIES INC | 26.86 | 41.49B | ||
| IQV | IQVIA HOLDINGS INC | 18.61 | 36.80B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.63 | 29.18B | ||
| WAT | WATERS CORP | 28.59 | 20.81B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.9 | 20.28B | ||
| ILMN | ILLUMINA INC | 28.33 | 18.99B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.9 | 16.43B | ||
| TEM | TEMPUS AI INC | N/A | 15.61B | ||
| ICLR | ICON PLC | 13.03 | 13.36B |
Related stock screener links
About CRL
Company Profile
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Company Info
CHARLES RIVER LABORATORIES
251 Ballardvale St
Wilmington MASSACHUSETTS 01887 US
CEO: James C. Foster
Employees: 18600
Phone: 17812226000
CHARLES RIVER LABORATORIES / CRL FAQ
What does CRL do?
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Can you provide the latest stock price for CHARLES RIVER LABORATORIES?
The current stock price of CRL is 180.07 USD. The price increased by 0.54% in the last trading session.
Does CHARLES RIVER LABORATORIES pay dividends?
CRL does not pay a dividend.
What is the ChartMill rating of CHARLES RIVER LABORATORIES stock?
CRL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting CRL stock to perform?
23 analysts have analysed CRL and the average price target is 192.74 USD. This implies a price increase of 7.04% is expected in the next year compared to the current price of 180.07.
Can you provide the number of employees for CHARLES RIVER LABORATORIES?
CHARLES RIVER LABORATORIES (CRL) currently has 18600 employees.
What is the market capitalization of CRL stock?
CHARLES RIVER LABORATORIES (CRL) has a market capitalization of 8.86B USD. This makes CRL a Mid Cap stock.
CRL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CRL. When comparing the yearly performance of all stocks, CRL turns out to be only a medium performer in the overall market: it outperformed 49.78% of all stocks.
CRL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRL. Both the profitability and the financial health of CRL get a neutral evaluation. Nothing too spectacular is happening here.
CRL Financial Highlights
Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.71. The EPS increased by 4.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| Debt/Equity | 0.7 |
CRL Forecast & Estimates
23 analysts have analysed CRL and the average price target is 192.74 USD. This implies a price increase of 7.04% is expected in the next year compared to the current price of 180.07.
For the next year, analysts expect an EPS growth of -0.31% and a revenue growth -0.98% for CRL